Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

Abstract

Denosumab was associated with increased bone mineral density at all sites and a reduction in the incidence of new vertebral fractures among men receiving androgen-deprivation therapy for nonmetastatic prostate cancer. (ClinicalTrials.gov number, NCT00089674.)